ReShape Lifesciences, Inc. (RSLS) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and thank you for joining the second quarter 2021 Reshape Life Sciences earnings webinar. I am pleased to be joined by Bart Fandy, Chief Executive Officer of Reshape Life Sciences, who will provide an overview of the company's recent activities and business highlights for the second quarter of 2021. Tom Stankovich, Chief Financial Officer of Reshape, will then review the financial results for the recent quarter and then turn the call back over to Bart to finish. As a reminder, this conference call, as well as Reshape Life Sciences SEC filings and website, including the investor information section of the website, contains forward-looking statements within the meaning of the Private Security Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risk, uncertainties, and other factors. These and additional risk and uncertainties are described more fully in the company's filings within the Securities and Exchange Commission, including those factors identified as risk factors in our annual report on Form 10-K and in our quarterly report on Form 10-Q that will be filed shortly. As an additional reminder, our stock is listed on the NASDAQ Capital Market trading symbol under ticker symbol RSLS. I will now turn the call over to the CEO, Bart Bandy. Bart? Thanks, Daniel. Good afternoon, everyone, and thank you for joining us today. The second quarter of 2021 proved to be a significant inflection point for Reshape, marked by the successful completion of our merger with Oberlin Therapeutics and listing on the NASDAQ capital market. Further driving this momentum, we raised $46 million through a warrant exercise agreement with existing accredited investors. Following the execution of this significant chai...